Your Health, We Care
Release date: 2024-08-13 18:00:29 Recommended: 117
Venetoclax is an oral anticancer drug targeting BCL-2 that promotes apoptosis of tumor cells by inhibiting the activity of BCL-2 protein. In China, venetoclax has been approved for the treatment of adult patients with acute myeloid leukemia who are not candidates for strong induction chemotherapy. The drug was initially used for chronic lymphocytic leukemia and has been progressively applied to a variety of hematological cancers such as multiple myeloma and lymphoma.
Clinical trial data from venetoclax have shown that:
In the VEN G group, the MRD negative rate reached 91% (122/134), indicating that the vast majority of patients had a significant reduction in the number of CLL cells in the peripheral blood and bone marrow in the short period of time after receiving combination therapy, reaching a state of deep remission. This high percentage of MRD negativity shows the robust efficacy of this treatment regimen.
The negative rate of MRD in peripheral blood remained at 58% (126/216) in the VEN G group, which was much higher than that in the GClb group (9% (20/216). This suggests that the therapeutic effect of venetoclax plus obinutuzumab persists even long after the end of treatment and is significantly better than that of the control group with obinutuzumab alone.
Patients should strictly follow the doctor's guidance when using venetoclax, pay attention to the side effects of the drug, according to the drug instructions, the adverse reactions of venetoclax are sorted out as follows:
Diarrhea may be mild, with more frequent and softer stools, or it may be severe with symptoms such as abdominal pain and dehydration. Patients should maintain adequate fluid intake and may be given antidiarrheal medications to relieve symptoms if necessary.
Neutropenia leads to a decrease in immunity, and patients are more susceptible to viral or bacterial infections, such as colds, pharyngitis, etc. Infection prevention and prompt treatment are key.
Lucius Pharmaceuticals' R&D team is a professional, efficient and innovative team that brings together top experts in the field of medicine. The team has always been guided by the needs of patients, committed to the research and development of new drugs, and constantly explored new treatments, striving to achieve more breakthroughs in the field of global medicine.
Adhering to the concept of cutting-edge technology, Lucius Pharmaceuticals is equipped with the industry's first-class pharmaceutical equipment. These machines have a high level of automation and intelligence to ensure the precision and efficiency of the pharmaceutical production process. From raw material screening to finished product packaging, every link is strictly controlled to ensure the quality and safety of products.
[Warm tips] The treatment of blood diseases is a long-term process, and patients should maintain a positive and optimistic attitude, actively communicate with the doctor, and take the medicine on time and in accordance with the doctor's instructions.
